CONCISE COMMUNICATION

Three cases of COVID-19 patients presenting with erythema

Masakazu TAMAI, Aya MAEKAWA, Noriko GOTO, Lindun GE, Tsutomu NISHIDA, Hiromi IWAHASHI, Akinori YOKOMI

Departments of Dermatology, Neurology, Gastroenterology, Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Japan

ABSTRACT

Individuals infected with the novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) who develop coronavirus disease 2019 (COVID-19) experience many symptoms; however, cutaneous manifestations are relatively rare. The authors encountered three patients with COVID-19 who presented with erythema and suspected viral rash. In all cases, erythema appeared after the onset of the initial symptoms of COVID-19. Erythema was considered to be caused by COVID-19 and not a drug-induced eruption because, in all cases, erythema was relieved merely by external medicine and oral antihistamines, without discontinuing the original medication. The authors’ hospital accepted 69 COVID-19 patients between 22 February 2020 and 31 May 2020 and, of these, three (4.3%) exhibited eruptions, and all cases presented erythema. Except for seven patients who exhibited positive nasopharyngeal swab tests for SARS-CoV-2 RNA but no symptoms, three (4.8%) of the remaining 62 patients exhibited erythema. Although various types of eruptions have been reported in patients with COVID-19, erythema was the only type in our patients. Erythema in the three patients exhibited many similarities to that previously reported in COVID-19 patients, particularly in the manner it appeared and disappeared. For these reasons, these three cases were considered typical examples of erythema in patients with COVID-19. Considering previous studies and the three cases reported here, there is a high probability that SARS-CoV-2 can cause erythema.

Key words: COVID-19, cutaneous manifestations, eruption, erythema, rash.

INTRODUCTION

Infections with the novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) resulting in coronavirus disease 2019 (COVID-19) have become widespread around the world. Between 22 February and 31 May 2020, 69 patients diagnosed with COVID-19 required hospitalization at our hospital. COVID-19 has a wide range of primary symptoms, including fever, cough, malaise and digestive symptoms; however, the frequency of cutaneous manifestations is comparatively lower. Various types of cutaneous manifestations have been reported, including erythema, urticaria, purpura, reticular and frostbite. There are, however, few reports of COVID-19 patients with erythema that include detailed information such as symptom progression. Herein, we report three patients with COVID-19 who presented with erythema suspicious for viral exanthema.

CASE REPORT

A 54-year-old man experiencing cough and slight fever (37°C) tested positive for SARS-CoV-2 RNA on nasopharyngeal swab 4 days after symptom onset, and was admitted to the authors’ hospital on day 5. Laboratory tests revealed normal white blood cell and platelet counts (6000 and 171 000/mm³, respectively), slightly impaired liver function (aspartate aminotransferase [AST], 31 IU/L; alanine aminotransferase [ALT], 45 IU/L) and an increased C-reactive protein level (5.6 mg/L). Chest radiography revealed a pattern suggestive of pneumonia. The patient’s comorbidities included bronchial asthma and hypertension, for which he used antihypertensive drugs and rescue bronchodilators. Inhaled ciclesonide and internal use of hydroxychloroquine and favipiravir was initiated on day 5. On day 11, the patient noticed a small itchy rash. On examination, multiple small erythematous papules with slight infiltrate on the extremities and trunk were observed (Fig. 1). No erosion, blistering, purpura or mucosal lesions were observed. Suspecting COVID-19-induced viral rash, topical steroids and oral antihistamines were started. On day 14, his fever resolved and erythema disappeared without pigmentation, and two consecutive negative polymerase chain reaction (PCR) tests were confirmed; the patient was discharged 26 days after onset.

A 24-year-old man with no comorbidity including allergic diseases, presented with fever (38°C) and, on day 8, a nasopharyngeal swab test was positive for SARS-CoV-2 RNA;
he was admitted to hospital and inhaled ciclesonide was started. Laboratory investigations revealed a low white blood cell count (3,100/mm³), normal platelet count (146,000/mm³), slightly impaired liver function (AST, 40 IU/L; ALT, 32 IU/L) and increased C-reactive protein level (47.5 mg/L). Chest computed tomography revealed a pattern suggestive of pneumonia. On day 10, the patient noticed an itchy rash. Physical examination revealed multiple papular erythemas with mild infiltration of the extremities and trunk, with some of which coalesced with adjacent lesions, and his face was mildly flushed with edema. No erosions, blistering, purpura or mucosal lesions were observed. Suspecting COVID-19-induced viral rash, topical steroids and oral antihistamines were started. p.o. administration of hydroxychloroquine was started on day 10; thereafter, fever resolved on day 15 and erythema disappeared without pigmentation on day 17. After two consecutive negative PCR tests were confirmed, the patient was discharged on day 19.

A 81-year-old woman with no comorbidity including allergic diseases, experiencing cough and slight fever (37°C), tested positive for SARS-CoV-2 RNA on nasopharyngeal swab on day 14, and was admitted to the authors’ hospital on day 16. After admission, inhaled ciclesonide was started. Laboratory investigations revealed a high white blood cell count (9,700/mm³), normal platelet count (267,000/mm³), slightly impaired liver function (AST, 44 IU/L; ALT, 31 IU/L) and increased C-reactive protein level (87.3 mg/L). Chest computed tomography revealed a pattern suggestive of pneumonia. On day 22, the patient noticed an itchy rash. Physical examination revealed multiple papular erythemas with mild infiltration of the extremities and trunk (Fig. 2). No erosions, blistering, purpura or mucosal lesions were observed. Suspecting COVID-19-induced viral rash, topical crotamiton and oral antihistamines were started, and erythema almost disappeared without pigmentation on day 26. After two consecutive negative PCR tests were confirmed, the patient was discharged on day 28.

**DISCUSSION**

The primary symptoms of COVID-19 include fever and dry cough; however, skin rashes are relatively rare. In a study by Recalcati, skin rash was recognized in 20.8% (18/88) of COVID-19 patients. In the only recent retrospective study, Hedou et al. reported that cutaneous manifestations of COVID-19 occurred in 4.9% (5/103) of patients. A review by Sachdeva et al. also reported that erythema was the most common, accounting for 47% of the total. In addition, there are reports of the erythema multiforme type. A search of the PubMed database retrieved only seven case reports describing COVID-19 patients with a rash that included basic patient information such as sex, age and course of rash; these reports are summarized in Table 1. The mean patient age was 47.1 years, with a range of 6-77 years. The number of days from the onset of COVID-19 symptoms to the appearance of erythema were between 0 and 30 days, and all cases exhibited erythema after the appearance of fever.

Our hospital accepted 69 COVID-19 patients between 22 February 2020 and 31 May 2020, of whom three (4.3%) exhibited eruptions, all of which were erythema. We excluded a patient who had a skin eruption approximately 2 weeks before the onset of COVID-19 symptoms because the eruption was unrelated. Except for seven patients with positive PCR for SARS-CoV-2, no symptoms, three of 62 patients (4.8%) exhibited erythema. In all cases, we did not alter the drug regimen before and after the erythema appeared, and the erythema improved with oral antihistamines and topical medicine; therefore, we considered that the possibility of drug-induced eruption was low. COVID-19 is a viral infection caused by SARS-CoV-2, and it has been reported that SARS-CoV-2 glycoproteins are present along with complement in skin blood vessels, which may induce viral rash. For this reason, we conclude that the erythema observed in our three cases was a viral rash and not a drug-induced eruption.
In all cases, erythema appeared after the onset of the initial symptoms of COVID-19 and improved with the alleviation of other symptoms, as described in other case reports. From this perspective, our cases can be considered to be typical examples of erythema that appear in COVID-19 patients.

One limitation of our study was that more patients in our hospital might have experienced cutaneous manifestation than we report. This is because it was difficult for us to perform a detailed examination of the patients’ skin (including biopsy) due to infection control measures against COVID-19, and we had to determine cutaneous manifestation depending only on the patient’s self-report. Some patients may fail to recognize eruption, or even if a patient is aware of eruption, more serious symptoms, such as dyspnea, may cause them to devote less attention to any eruption. Second, the number of COVID-19 patients in our hospital was limited to 69, and our hospital specializes only in those with mild to moderate COVID-19 (i.e. those who do not require artificial respiration). As such, the patients at our hospital cannot be regarded as truly representative of the entire COVID-19 population. Third, there were 69 cases in our hospital, of whom four were transferred to another hospital and seven were still under treatment; therefore, we did not observe the entire disease course. It is possible that a skin rash might have been present in some of these cases.

Based on our experience and those described in other reports, it is highly possible that SARS-CoV-2 can cause erythema. COVID-19 is an emerging infectious disease, and it is hoped that further analysis of cutaneous manifestations will be performed and reported as the number of cases accumulate.

ACKNOWLEDGMENTS: We thank all of our hospital staff who contribute to the treatment of COVID-19 patients.

CONFLICT OF INTEREST: None declared.

REFERENCES
1. Guan W, Ni Z, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-1720.
2. Zhang JJ, Dong X, Cao YY. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7): 1730-1741.
3. Sachdeva M, Gianotti R, Shah M et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermo Sci 2020; 98(2): 75-81.
4. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34(5): e212-e213.
5. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on “Cutaneous manifestations in...
COVID-19: a first perspective by Recalcati S. J Eur Acad Dermatol Venereol 2020; 4(7): e299–e300.

6 Galván Casas C, Catalá A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183(1): 71–77.

7 Jimenez-Cauhe J, Ortega-Guiliano D, Carretero-Barrio I et al. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol 2020; https://doi.org/10.1111/ced.14281

8 Mahé A, Bircel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with Coronavirus Disease 2019? J Eur Acad Dermatol Venereol 2020; 34(6): e246–e247.

9 Zengarini C, Orioni G, Cascavilla A et al. Histological pattern in COVID-19-induced viral rash. J Eur Acad Dermatol Venereol 2020; https://doi.org/10.1111/jdv.16569

10 Ahouach B, Harant S, Ullmer A et al. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol 2020; https://doi.org/10.1111/bjd.19168

11 Rivera-Oyola R, Koschitzky M, Printy R et al. Dermatologic findings in 2 patients with COVID-19. JAAD Case Rep 2020; 6(6): 537–539.

12 Paolino G, Canti V, Raffaele Mercuri S, Rovere Querin P, Candiani M, Pasi F. Diffuse cutaneous manifestation in a new mother with COVID-19 (SARS-Cov-2). Int J Dermatol 2020; 59(7): 874–875.

13 Morey-Olivé M, Espiau M, Mercadal-Hally M, Lera-Carballo E, García-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). An Pediatr (Engl Ed) 2020; 92(6): 374–375.

14 Amatore F, Macagno N, Mailhe M et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol 2020; 34(7): e304–e306.

15 Magro C, Mulvey JJ, Berlin D et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1–13.